相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
Piro Lito et al.
SCIENCE (2016)
Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State
Matthew P. Patricelli et al.
CANCER DISCOVERY (2016)
Enhanced MET Translation and Signaling Sustains K-Ras-Driven Proliferation under Anchorage-Independent Growth Conditions
Saori Fujita-Sato et al.
CANCER RESEARCH (2015)
Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers
Sally Temraz et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2015)
Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis
Harry R. Bueller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
High-throughput screening identifies small molecules that enhance the pharmacological effects of oligonucleotides
B. Yang et al.
NUCLEIC ACIDS RESEARCH (2015)
Long-circulating siRNA nanoparticles for validating Prohibitin1-targeted non-small cell lung cancer treatment
Xi Zhu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer
David Hong et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Predictive Dose-Based Estimation of Systemic Exposure Multiples in Mouse and Monkey Relative to Human for Antisense Oligonucleotides With 2 '-O-(2-Methoxyethyl) Modifications
Rosie Z. Yu et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2015)
MEK and PI3K inhibition in solid tumors: rationale and evidence to date
E. Jokinen et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2015)
Targeting RAS-mutant Cancers: Is ERK the Key?
Meagan B. Ryan et al.
TRENDS IN CANCER (2015)
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
Christopher J. Caunt et al.
NATURE REVIEWS CANCER (2015)
Therapeutic Targeting of Oncogenic K-Ras by a Covalent Catalytic Site Inhibitor
Sang Min Lim et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2014)
Disruption of CRAF-Mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant Tumors
Piro Lito et al.
CANCER CELL (2014)
Drugging the undruggable RAS: Mission Possible?
Adrienne D. Cox et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice
Thazha P. Prakash et al.
NUCLEIC ACIDS RESEARCH (2014)
KRAS: feeding pancreatic cancer proliferation
Kirsten L. Bryant et al.
TRENDS IN BIOCHEMICAL SCIENCES (2014)
Requirement for Interaction of PI3-Kinase p110α with RAS in Lung Tumor Maintenance
Esther Castellano et al.
CANCER CELL (2013)
Lactate Dehydrogenase B Is Required for the Growth of KRAS-Dependent Lung Adenocarcinomas
Mark L. McCleland et al.
CLINICAL CANCER RESEARCH (2013)
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Jonathan M. Ostrem et al.
NATURE (2013)
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway
Jaekyoung Son et al.
NATURE (2013)
Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers
Georgia Hatzivassiliou et al.
NATURE (2013)
Mutant KRAS is a druggable target for pancreatic cancer
Elina Zorde Khvalevsky et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
Erick J. Morris et al.
CANCER DISCOVERY (2013)
MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors
Alexa B. Turke et al.
CANCER RESEARCH (2012)
Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism
Haoqiang Ying et al.
CELL (2012)
Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice
Meredith A. Collins et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Patient-derived tumour xenografts as models for oncology drug development
John J. Tentler et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
RNA therapeutics: beyond RNA interference and antisense oligonucleotides
Ryszard Kole et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
TricycloDNA-modified oligo-2′-deoxyribonucleotides reduce scavenger receptor B1 mRNA in hepatic and extra-hepatic tissues-a comparative study of oligonucleotide length, design and chemistry
Sue Murray et al.
NUCLEIC ACIDS RESEARCH (2012)
A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma
Eric A. Collisson et al.
CANCER DISCOVERY (2012)
c-Raf, but Not B-Raf, Is Essential for Development of K-Ras Oncogene-Driven Non-Small Cell Lung Carcinoma
Rafael B. Blasco et al.
CANCER CELL (2011)
Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes
Erich Koller et al.
NUCLEIC ACIDS RESEARCH (2011)
Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
Jonathan R. Dry et al.
CANCER RESEARCH (2010)
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
Frederick J. Raal et al.
LANCET (2010)
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Mark E. Davis et al.
NATURE (2010)
A Gene Expression Signature Associated with K-Ras Addiction Reveals Regulators of EMT and Tumor Cell Survival
Anurag Singh et al.
CANCER CELL (2009)
Antisense oligonucleotide pharmacokinetics and metabolism
Richard S. Geary
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2009)
Short Antisense Oligonucleotides with Novel 2′-4′ Conformationaly Restricted Nucleoside Analogues Show Improved Potency without Increased Toxicity in Animals
Punit P. Seth et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Binding of Ras to phosphoinositide 3-kinase p110α is required for Ras-driven tumorigenesis in mice
Surbhi Gupta et al.
CELL (2007)
Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor
Tammie C. Yeh et al.
CLINICAL CANCER RESEARCH (2007)
Knockdown of mutant K-ras expression by adenovirus-mediated siRNA inhibits the in vitro and in vivo growth of lung cancer cells
Zhiping Zhang et al.
CANCER BIOLOGY & THERAPY (2006)
Lonafarnib in cancer therapy
Floriana Morgillo et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2006)
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors
EW Song et al.
NATURE BIOTECHNOLOGY (2005)
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer
E Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes
GH Fisher et al.
GENES & DEVELOPMENT (2001)
分享论文
